Felicia Cosman is Professor of Clinical Medicine at Columbia University College of Physicians and Surgeons in New York City, NY. She is a graduate of Cornell University in Ithaca, NY, and Stony Brook Medical School in Stony Brook, NY. Dr. Cosman received her internal medicine training and completed her endocrinology fellowship at Columbia-Presbyterian Medical Center in New York City. She was Medical Director of the Clinical Research Center and an osteoporosis specialist at Helen Hayes Hospital for 30 years.
Dr. Cosman’s research includes studies on the causes of osteoporosis and how estrogen, SERMs, vitamin D, bisphosphonates, denosumab, and anabolic therapies work as treatments for osteoporosis. She has also studied the causes of stress fractures and factors influencing the acquisition of peak bone mass during youth, as well as identifying patient factors, which should prompt targeted screening for vertebral fractures. A major research focus over the last decade has been on the use of bone-building medications (teriparatide, abaloparatide and romosozumab). She is a major thought leader in studies of treatment sequences and combinations, long-term treatment paradigms and goal-directed osteoporosis therapy.
Dr. Cosman is the recipient of multiple research grants from the NIH, the Department of Defense, the National Multiple Sclerosis Society, and multiple pharmaceutical companies. She has published more than 150 peer-reviewed articles in the field of osteoporosis. Most recently, she was selected as Editor-in-Chief of the journal Osteoporosis International.
Dr. Cosman disclosed the following conflicts of interest for this workshop:
- Amgen: Advising, Consulting, Speaking, Research Grants and Medication
- Eli Lilly: Advising, Consulting, Speaking, Research Medication
- Merck: Advising
- Radius: Advising, Consulting, Speaking
- Tarsa/RPharm: Consulting